Tandem has received FDA approval for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type 1 diabetes mellitus.

The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out ...

Abbott (ABT) trades at $100.69 with a 24/7 Wall St. price target of $125.10 (24.24% upside) on a buy recommendation with 90% confidence. FreeStyle Libre CGM sales hit $2B in Q4 2025 with 15% year-over ...

Please provide your email address to receive an email when new articles are posted on . Patients using the MiniMed 780G had a small increase in time in range after switching to the Instinct CGM sensor ...

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 ...

The FDA designated this a Class I Recall after 860 serious injuries and 7 deaths were reported related to falsely low glucose readings. Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and ...

Abbott Diabetes Care has advised that certain glucose monitor sensors be removed from use or sale after the FDA classified the action as its most serious type of recall. The recall involves specific ...

Feb. 4 (UPI) --Officials for Abbott Diabetes Care have recalled some of the company's FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitor sensors for people with diabetes. The Food ...